Emma Rybalka

The paper identifies ADSS1 as a suppressed metabolic control node in dystrophic muscle, showing its role in purine metabolism and its impact on inflammatory and adipogenic remodelling.

This study shows that stress reveals impaired endocrine coordination of glucose metabolism in dystrophin deficiency, with interventions improving glucose control and muscle function.

This study uses multimodal non-invasive assessments to characterize structural and functional alterations in ADSS1 myopathy, identifying biomarkers for disease monitoring.

This study shows that the AML chemotherapy regimen induces cachexia in mice, characterized by body and lean mass loss, and identifies haptoglobin as a potential biomarker for chemotherapy-induced cachexia.

This study shows that moderate-term dimethyl fumarate treatment reduces dystrophic muscle pathology in a mouse model of Duchenne muscular dystrophy, with anti-inflammatory, anti-fibrotic, and anti-lipogenic effects.

This study shows that estrogen loss in female mdx mice reduces exercise capacity and mitochondrial metabolism, but estrogen replacement therapy can reverse these effects and upregulate Rbm20.